× Industry Reports Services Press Release Contact us About us

European Monoclonal Antibodies Market revenue to hit $106 Bn by 2027

 Request a sample

European Monoclonal Antibodies Market size is expected to exceed USD 106 billion by 2027, according to a latest forecast report by Graphical Research.

Growing therapeutic applications of monoclonal antibodies (mAbs) in several disease treatment will excel product demand in the monoclonal antibodies market. Highly specific targeted therapies for range of severe chronic diseases such as cancer, autoimmune diseases and cardiovascular diseases influences product demand. Further, mAb potential in treatment of rare diseases has driven R&D activities in the field. Extensive product pipeline with potential effective therapies will result in number of product launches in future.

Strong focus on research and development activities with increasing investment on product development will help industry players to tap untapped growth opportunities in the market. The companies are leveraging their expertise to develop novel mAb therapies to treat several complex diseases. For instance, AbbVie entered in collaborative agreement with I-Mab for the development and commercialization of an innovative anti-CD47 monoclonal antibody, Lemzoparlimab, discovered for the treatment of multiple cancers.

COVID-19 pandemic has positively impacted the development and commercialization of mAb treatment therapies. This will ultimately impel the business growth with use of several monoclonal antibodies to treat COVID-19 patients. As mAbs are capable of neutralizing infection and reduce risk of mortality, the industry has experienced high growth potential during pandemic and will continue to grow at faster pace in future.

Browse detailed statistical insights from the report, “Europe Monoclonal Antibodies Market Forecast 2027 By End-use (Hospitals, Clinics), By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), Research Report, Country Outlook (Germany, UK, France, Spain, Italy, Denmark, Sweden, Poland, The Netherlands, Belgium, Romania, Czech Republic), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @


Fully human monoclonal antibodies segment held majority of revenue share accounting for around USD 22.3 billion revenue in 2020. The major growth attributable factors are specificity to human genomes and integration of advanced genetic technologies leading to highly efficient product launches. Further, collaborative efforts by leading pharmaceutical and clinical stage development firms will create segment growth opportunities. Recently, Sanofi entered in agreement to acquire Kymab, a company developing fully human monoclonal antibodies to target immune-mediated diseases along with immuno-oncology therapeutics.

Oncology segment is forecasted to progress at 13.3% CAGR during the analysis timeframe. High prevalence rate of cancer among European population will spur demand for mAb in treatment therapies. According to the World Health Organization, nearly 3.7 million new cases associated with cancer are reported each year in the region.

Hospitals segment dominated the market with nearly 42% revenue share in 2020. Increasing hospitalizations with high demand of specialty treatment for infectious diseases, cancer and autoimmune diseases will propel the product demand in facilities. Furthermore, acceptance of monoclonal antibodies by specialties and usage of innovative therapies in hospitals will stimulate product adoption in regional facilities. Government initiatives and reimbursement policies regarding high-cost treatment drive patient preference for hospitals, thereby augmenting the segment growth in foreseeable future.

UK monoclonal antibodies market is anticipated to proceed at 13.7% CAGR between 2021 to 2027. Booming demand for monoclonal antibody therapeutics owing to increasing incidence of autoimmune and cancer will surge industry growth. Further, expanding availability and accessibility will benefit domestic market. Increasing healthcare expenditure and disposable income also enhances affordability of high-cost and innovative therapies. Additionally, business expansion of biopharmaceutical companies in the country will impel product supply.

Europe monoclonal antibodies market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2016 to 2027, for the following segments:

Europe Market, By Type

  • Fully Human
  • Humanized
  • Chimeric
  • Others

Europe Market, By Application

  • Oncology
  • Autoimmune diseases
  • Infectious diseases
  • Others

Europe Market, By End-use

  • Hospitals
  • Clinics
  • Others

The above information has been provided for the following countries:

  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Poland
    • The Netherlands
    • Belgium
    • Romania
    • Czech Republic
    • Others